APA
Salwender H., Bertsch U., Weisel K., Duerig J., Kunz C., Benner A., Blau I. W., Raab M. S., Hillengass J., Hose D., Huhn S., Hundemer M., Andrulis M., Jauch A., Seidel-Glaetzer A., Lindemann H., Hensel M., Fronhoffs S., Martens U., Hansen T., Wattad M., Graeven U., Munder M., Fenk R., Haenel M., Scheid C. & Goldschmidt H. (20191125). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. : BMC cancer.
Chicago
Salwender Hans, Bertsch Uta, Weisel Katja, Duerig Jan, Kunz Christina, Benner Axel, Blau Igor W, Raab Marc Steffen, Hillengass Jens, Hose Dirk, Huhn Stefanie, Hundemer Michael, Andrulis Mindaugas, Jauch Anna, Seidel-Glaetzer Andrea, Lindemann Hans-Walter, Hensel Manfred, Fronhoffs Stefan, Martens Uwe, Hansen Timon, Wattad Mohammed, Graeven Ullrich, Munder Markus, Fenk Roland, Haenel Mathias, Scheid Christof and Goldschmidt Hartmut. 20191125. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. : BMC cancer.
Harvard
Salwender H., Bertsch U., Weisel K., Duerig J., Kunz C., Benner A., Blau I. W., Raab M. S., Hillengass J., Hose D., Huhn S., Hundemer M., Andrulis M., Jauch A., Seidel-Glaetzer A., Lindemann H., Hensel M., Fronhoffs S., Martens U., Hansen T., Wattad M., Graeven U., Munder M., Fenk R., Haenel M., Scheid C. and Goldschmidt H. (20191125). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. : BMC cancer.
MLA
Salwender Hans, Bertsch Uta, Weisel Katja, Duerig Jan, Kunz Christina, Benner Axel, Blau Igor W, Raab Marc Steffen, Hillengass Jens, Hose Dirk, Huhn Stefanie, Hundemer Michael, Andrulis Mindaugas, Jauch Anna, Seidel-Glaetzer Andrea, Lindemann Hans-Walter, Hensel Manfred, Fronhoffs Stefan, Martens Uwe, Hansen Timon, Wattad Mohammed, Graeven Ullrich, Munder Markus, Fenk Roland, Haenel Mathias, Scheid Christof and Goldschmidt Hartmut. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. : BMC cancer. 20191125.